Related Experiment Video
Updated: Mar 21, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
New expectations in the treatment of anemia in chronic kidney disease
Juan M López-Gómez1, Soraya Abad1, Almudena Vega1
1Servicio de Nefrología, Hospital Universitario Gregorio Marañón, Madrid, España.
Abstract:
The new drugs developed for the treatment of anemia in chronic kidney disease patients, together with their mechanisms of action are reviewed. At present, many of them are already in advanced stages of clinical trials and is expected to be incorporated into the therapeutic arsenal in the coming years. The potential benefits and possible limitations are also described.
Insights
New drugs for anemia in chronic kidney disease (CKD) patients are under review, detailing mechanisms, benefits, and limitations. These novel treatments are nearing clinical application, offering new hope for CKD anemia management.
Area of Science:
- Nephrology
- Pharmacology
- Hematology
Background:
- Anemia is a common complication in patients with chronic kidney disease (CKD).
- Current treatments for CKD-related anemia have limitations.
- Novel therapeutic strategies are needed to address this unmet medical need.
Purpose of the Study:
- To review newly developed drugs for treating anemia in chronic kidney disease patients.
- To describe the mechanisms of action of these new drugs.
- To discuss the potential benefits and limitations of these emerging therapies.
Main Methods:
- Literature review of recent scientific publications and clinical trial data.
- Analysis of drug development pipelines for CKD anemia.
- Synthesis of information on drug efficacy, safety, and patient outcomes.
Main Results:
- Several new drug candidates targeting anemia in CKD are in advanced clinical trial stages.
- These drugs employ diverse mechanisms of action, including novel erythropoiesis-stimulating agents and HIF-PH inhibitors.
- Early data suggest promising efficacy and manageable safety profiles for some agents.
Conclusions:
- The therapeutic landscape for CKD-associated anemia is evolving with promising new drug options.
- These novel treatments are expected to become available in the near future, potentially improving patient care.
- Careful consideration of individual patient profiles and potential limitations will be crucial for optimal treatment selection.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury VI: Nursing Management

